Literature DB >> 20825300

Lethal, malignant, metastatic struma ovarii.

Pierre-Yves Marcy1, Juliette Thariat, Danielle Benisvy, Pierre Azuar.   

Abstract

BACKGROUND: Struma ovarii (SO) is extremely rare, with less than 200 reported cases in the medical literature. SO is defined by the presence of an ovarian tumor containing thyroid tissue as the predominant cell type. Malignant transformation is rare and lethal cases of SO are even rarer. We report on a patient presenting with left ovarian cystic SO and lethal outcome.
SUMMARY: A 45-year-old woman was diagnosed with a follicular variant of papillary carcinoma on laparotomy and left salpingo-oophorectomy. She had persistently elevated serum thyroglobulin following total thyroidectomy + radioiodine and second-look surgery. Imaging scan analysis showed pelvic tumor recurrence and hypervascular liver metastases during follow-up as well as peritoneal carcinomatosis in the pelvis, right abdominal wall, and malignant ascites. The patient died from cachexia at 37 months after diagnosis.
CONCLUSIONS: Such an aggressive malignant disease and lethal course of SO is rare. Total thyroidectomy is mandatory to exclude a primary thyroid neoplasm and for radioiodine therapy and follow-up. SO may spread to contralateral ovary, pelvic nodes, peritoneum, liver, lungs, and bones through hematogeneous spread, which is different from the dissemination pattern of papillary thyroid carcinomas. Imaging highlights the mixed behavior of this ovarian tumor.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20825300     DOI: 10.1089/thy.2010.0022

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  9 in total

Review 1.  Teratoma with somatic-type malignant components of the testis. A review and an update.

Authors:  Gregor Mikuz; Maurizio Colecchia
Journal:  Virchows Arch       Date:  2012-05-24       Impact factor: 4.064

2.  Metastatic follicular struma ovarii complicating pregnancy: a case report and review of the literature.

Authors:  Woohyung Lee; Nam-Joon Yi; Hyeyoung Kim; Youngrok Choi; Minsu Park; Geun Hong; June Young Choi; Hyun Hoon Chung; Kwang-Woong Lee; Do-Joon Park; Hye Sook Min; June-Key Chung; Kyung-Suk Suh
Journal:  Korean J Hepatobiliary Pancreat Surg       Date:  2012-08-31

3.  Follicular carcinoma arising from struma ovarii. A case report.

Authors:  Faten Limaiem; Saadia Bouraoui
Journal:  Pathologica       Date:  2020-12

4.  Struma ovarii with follicular thyroid-type carcinoma and neuroendocrine component: case report.

Authors:  Federico Selvaggi; Domenico Risio; Mathew Waku; Daniela Simo; Domenico Angelucci; Alberto D'Aulerio; Roberto Cotellese; Paolo Innocenti
Journal:  World J Surg Oncol       Date:  2012-05-21       Impact factor: 2.754

5.  Malignant Struma ovarii in a 30-year old nulliparous patient.

Authors:  J Colin Boyd; Blair A Williams; Matthew H Rigby; Katharina Kieser; Saul Offman; Hemlata Shirsat; Jonathan R B Trites; S Mark Taylor; Robert D Hart
Journal:  Thyroid Res       Date:  2017-05-30

6.  Unusual Case of Malignant Struma Ovarii and Cervical Thyroid Cancer Preceded by Ovarian Teratoma: Case Report and Review of the Literature.

Authors:  Elias G Tzelepis; Elena Barengolts; Steven Garzon; Joseph Shulan; Yuval Eisenberg
Journal:  Case Rep Endocrinol       Date:  2019-03-17

7.  Survival Outcomes and Prognostic Predictors in Patients With Malignant Struma Ovarii.

Authors:  Sijian Li; Shujun Kong; Xiaoxue Wang; Xinyue Zhang; Min Yin; Jiaxin Yang
Journal:  Front Med (Lausanne)       Date:  2021-12-23

8.  Neuroendocrine Tumors: Clinical, Histological and Immunohistochemical Perspectives and Case Report-Mature Teratoma in a 16-Year-Old Girl.

Authors:  Elżbieta Sowińska-Przepiera; Dariusz Starzyński; Anhelli Syrenicz; Ireneusz Dziuba; Barbara Wiszniewska; Sylwia Rzeszotek
Journal:  Pathophysiology       Date:  2021-08-27

9.  Malignant struma ovarii with papillary carcinoma combined with retroperitoneal lymph node metastasis: A case report.

Authors:  Wen Xiao; Jin-Rong Zhou; Dong Chen
Journal:  World J Clin Cases       Date:  2022-03-26       Impact factor: 1.337

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.